#Japan Pet Cancer Therapeutics Market | Explore Tumblr Posts and Blogs

rohit890 · 2 years

Text

Clinical Trial Imaging Market 5.9% CAGR Projection Over The Next Five Years

Market Overview

Clinical Trial Imaging is the use of imaging modalities, analysis services, and software to ascertain the effectiveness of innovative drugs before they are made available for purchase. Clinical imaging methods are being utilised more frequently in oncology treatment trials to demonstrate the efficacy and safety of the drug. Positron Emission Tomography (PET), Optical Coherence Tomography (OCT), Magnetic Resonance Imaging (MRI), and Ultrasound are the imaging technologies most frequently employed in clinical trials. During the projection period, the market is anticipated to be driven by the rise in cancer diagnoses and deaths globally. However, it is anticipated that the industry's growth prospects will be constrained by the severe government regulations in the field.

View Detailed Report Description: https://www.globalinsightservices.com/reports/clinical-trial-imaging-market/

Market Dynamics

The most important aspect, like an increase in R&D expenditures, is an increase in R&D expenditures. Companies in the pharmaceutical and biotechnology industries spend a lot of money on research to create novel compounds. The market for clinical trial imaging is predicted to grow as a result of rising government and pharmaceutical R&D spending as well as a growing emphasis on life science projects to create new therapeutic and diagnostic products. Similarly, developing nations like India, South Korea, Brazil, and Mexico present substantial potential opportunities to market participants in clinical trial imaging, primarily as a result of the rising R&D investment in these nations.

A notable trend in these emerging markets is the commercialization of life science research. These economies are expected to present the clinical trial imaging market with substantial growth prospects due to considerable advancements in life sciences research. Additionally, there are other CROs that provide drug development services to pharmaceutical and biotechnology businesses in Asian markets, particularly China and India. The need for clinical trial imaging is predicted to rise in emerging nations in the next years due to the large increase in R&D spending and CROs operating in these nations.

The key players in the global clinical trial imaging market are ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace Klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US).

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

Global Insight Services LLC

16192, Coastal Highway, Lewes DE 19958

E-mail: [email protected]

Phone: +1–833–761–1700

2 notes · View notes

ellinapark · 1 year

Text

Radiopharmaceuticals in Nuclear Medicine Market to Eyewitness Massive Growth by 2028

The Latest Released market study on Global Radiopharmaceuticals in Nuclear Medicine market provides information and useful stats on market structure, size and trends. The report is intended to provide cutting-edge market intelligence and strategic insights to help decision makers take sound investment decisions and identify potential gaps and growth opportunities. Besides, the report also identifies and analyses changing dynamics, emerging trends along with essential drivers, challenges, opportunities and restraints in Radiopharmaceuticals in Nuclear Medicine market. What’s keeping:

Cardinal Health (United States)

GE Healthcare (United States)

Curium (France)

Lantheus Medical Imaging (United States)

Bayer AG (Germany)

Bracco Imaging (Italy)

EczacÃ½baÃ¾Ã½-Monrol Nuclear Products (Turkey)

Nordion (Canada)

Advanced Accelerator Applications (France)

NTP Radioisotopes (South Africa)

Keep Growing in the Market? Benchmark yourself with the strategic moves and latest Market Share and Sizing of Global Radiopharmaceuticals in Nuclear Medicine market recently published by AMA Radiopharmaceuticals are radioactive compounds that have a bound radionuclide in their structure, whose purpose is directing the radionuclide to a location to be treated or to obtain images. Nuclear medications, also known as radiopharmaceuticals, are used to treat lymphoma and bone metastases. Nuclear medicines such as F-18, Tc-99, Ga-67, and I-123 are used in diagnostic operations, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are employed in therapeutic procedures. In comparison to chemotherapy, the convenience of treatment using minimally invasive approaches attracts more people to radiopharmaceuticals. The radiopharmaceuticals industry is driven by the rising number of cardiac patients and the development of clear imaging techniques using diagnostic equipment such as PET and SPECT. Supply constraints, logistical challenges, and a scarcity of skilled medical professionals are among the problems limiting the market's growth.

The Radiopharmaceuticals in Nuclear Medicine Market segments and Market Data Break Down 24360

On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa. What’s Trending in Market: High Demand due to increasing Initiatives to reduce the demand and supply gap of Mo-99

Market Challenges: Hospital budget cuts and high equipment costs

Market Opportunities: Use of radiopharmaceuticals in neurological applications

Highlights of Influencing Drivers: Rising incidence as well as prevalence of target conditions

Huge Development of alpha-radioimmunotherapy-based targeted cancer treatments

Presented By

AMA Research & Media LLP

0 notes

petnews2day · 2 years

Text

Research on 3D Computed Tomography Software Market Revenue, Future Growth, Trends, Application, Top Key Players, Business Opportunities Forecast to 2029

New Post has been published on https://petnews2day.com/pet-industry-news/pet-travel-news/research-on-3d-computed-tomography-software-market-revenue-future-growth-trends-application-top-key-players-business-opportunities-forecast-to-2029/

Research on 3D Computed Tomography Software Market Revenue, Future Growth, Trends, Application, Top Key Players, Business Opportunities Forecast to 2029

Global 3D Computed Tomography Software Market which is expected to undergo a healthy CAGR during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

The 3D CT used as a preoperative planning tool, the surgeon may better understand the osteophytic areas that need treatment, extend the range of motion, and produce a good outcome. PET and single photon emission computed tomography are the two examples of computed tomography. The purpose of PET was to measure cerebral blood flow and glucose metabolism using radiolabelled tracer molecules. A scanner that detects radiation emitted by the tracer compound using a cylindrical detector encircling the subject is used to determine the distribution of these tracers in the brain.

3D Computed Tomography Software Market is the matchless market research report that conducts industry analysis on products, markets, companies, industries and many countries internationally. Market information related to specific stock, currency, commodity and geographic region or country has also been analysed in this report. The report deals with abundant parameters in detail to suit the requirements of business or clients. These parameters range from latest trends, market segmentation, new market entry, industry forecasting, target market analysis, future directions, opportunity identification, and strategic analysis to insights and innovation. All of these are analyzed and evaluated by a team of innovative, enthusiastic, and motivated researchers and forecasters so that nothing lefts uncovered in the wide-ranging 3D Computed Tomography Software Market report.

Get a Sample PDF of 3D Computed Tomography Software Market report – https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-3d-computed-tomography-software-market

3D Computed Tomography Software Market Leading Key Players:

Canon India Pvt Ltd. (Japan)

FUJIFILM Corporation (Japan)

General Electric (U.S.)

Hitachi, Ltd. (Japan)

Koning health (U.S.)

Koninklijke Philips N.V (Netherlands)

NeuroLogica Corp. (U.S.)

Neusoft Corporation (U.S.)

Siemens (Germany)

Shenzhen Anke High-Tech Co., Ltd (China)

Global 3D Computed Tomography Software Market Dynamics:

Drivers

3D computed tomography software use in veterinary clinic

3D images can be printed as a 3D anatomical models for a better understanding of the anatomy to veterinary students, which helps anatomy students in enhanced learning and also helps them to diagnose and treat many anatomical disorders in the body. The 3D CT images provided a better understanding of the anatomical CT cross sections.

Usage of computed tomography

The use of computed tomography (CT) in diagnostic imaging is crucial for assessing a wide range of clinical disorders. Iterative reconstruction methods, dual-energy CT, cone-beam CT, portable CT, and phase-contrast CT are just a few of the important advancements in CT technology that have recently occurred and are anticipated to have a substantial therapeutic impact.

Increasing prevalence of chronic diseases and other medical conditions

The demand for diagnostic testing is driven by the rising prevalence of numerous chronic diseases and other medical issues as a result of unhealthy lifestyles or other factors. Cancer diagnosis frequently involves the use of computed tomography. According to estimates, there are over 523 million cases of cardiovascular disorders and 19.3 million cases of cancer worldwide. This will boost the market growth.

Opportunities

Innovations and advancements in the computed tomography technology

To maintain a competitive edge in the computed tomography industry, computed tomography manufacturers make significant investments in innovation for their modalities. They work to include new hardware and software features, iterative reconstruction, more sensitive detectors that create less electronic noise, and other innovations into CT scan modalities. For instance, medical 3D imaging can now be performed using a variety of modalities, including computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasonography (US), among others, CT data produces the highest quality images, and CT images are now the most commonly used source of data for 3D simulation and navigation images.

Restraints/Challenges

High cost of computed tomography modality

One of the main reasons limiting the market’s growth is the high price of computed tomography systems. Financial limitations, healthcare facilities, particularly those in emerging and low-income nations, are often hesitant to acquire cutting-edge medical technologies such as computed tomography.

This 3D computed tomography software market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the 3D computed tomography software market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

In August 2021, Bausch & Lomb and Lochan entered into an agreement to develop the next-generation of eyetelligence

, a clinical decision support software.

In January 2021, Fotona launched Time Walker® Intima Laser

, the latest device for performing non-invasive gynecological procedures.

In May 2021, Cellini acquires Nano scribe for €50m to buy into two-photon polymerization. A manufacturing service company named FreeFORM Technologies used ExOne’s binder jet 3D printing technology to create lightweight car equipment. As a part of an industrial automation system, this intricate end-of-arm tooling component is made of 17-4PH stainless steel and is intended to be combined with a six-axis FANUC robot. Binder jet technology from the ExOne Innovent+ 3D printer enables FreeFORM to produce parts with less weight and lower manufacturing costs.

To Gain More Insights into the 3D Computed Tomography Software Market Analysis, Browse Summary of the Research [email protected] https://www.databridgemarketresearch.com/reports/global-3d-computed-tomography-software-market

Global 3D Computed Tomography Software Market Scope and Market Size

The 3D Computed Tomography Software Market is segmented on the basis of types, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

Body Scanning Software

Animal Scanning Software

Application

Human

Veterinary

Research

End User

Hospital

Diagnostic Center

Research

Veterinary Clinic

3D Computed Tomography Software Market Country Level Analysis

The 3D Computed Tomography Software Market is analyzed and market size insights and trends are provided by country, type, deployment and end user pas referenced above.

The countries covered in the 3D Computed Tomography Software Market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the 3D Computed Tomography Software Market because of the presence of favorable regulatory scenario and high adoption of HCIT solutions within the region. Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to the presence of a large number of healthcare IT companies in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Browse the complete table of contents at 3D Computed Tomography Software Market – https://www.databridgemarketresearch.com/toc/?dbmr=global-3d-computed-tomography-software-market

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The 3D Computed Tomography Software Market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for 3D Computed Tomography Software Market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the 3D Computed Tomography Software Market. The data is available for historic period 2010-2020.

Competitive Landscape and 3D Computed Tomography Software Market Share Analysis

The 3D Computed Tomography Software Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to 3D Computed Tomography Software Market.

Report Coverage:

Major growth drivers, restraining factors, opportunities, and potential challenges for the market.

Comprehensive insights into the regional developments.

List of major industry players.

Key strategies adopted by the market players.

Latest industry developments include product launches, partnerships, mergers, and acquisitions.

Why buy this report?

The report offers a comprehensive evaluation of the Global & Regional Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.

The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.

The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.

The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.

The report also contains the competitive analysis using Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.

Top Healthcare Report:

Global Teleradiology Market – Industry Trends and Forecast to 2028

Asia-Pacific Tel3D Computed Tomography Software Market – Industry Trends and Forecast to 2029

Global Mobile Cardiac Telemetry (MCAT) Market – Industry Trends and Forecast to 2028

Middle East and Africa Mobile Cardiac Telemetry (MCT) Market – Industry Trends and Forecast to 2028

North America Mobile Cardiac Telemetry (MCT) Market – Industry Trends and Forecast to 2028

About Data Bridge Market Research, Private Ltd

Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[email protected]

#Pet Travel News

0 notes

researchinhealthcare · 3 years

Text

Radiopharmaceuticals Market Research Report that Helps to Identify New Business Opportunities in 2027

Radiopharmaceuticals Market Highlights :

Global Radiopharmaceuticals Market is expected to register a CAGR of 8.10% during the forecast period, with a market value of USD 15,060.87 Million till 2025.

Radiopharmaceuticals are radioactive compounds or nuclear medicines that find diagnostic and therapeutic applications in the medical industry. The radioactive particles are used in medical imaging to diagnose diseases and to treat cancer through targeted therapy.

The global radiopharmaceutical market is expected to exhibit an exponential growth during the forecast period, owing to the increasing prevalence of chronic diseases such as cancer, the growing use of radioisotopes in the healthcare industry, increasing application of radiopharmaceuticals for the diagnosis & treatment of chronic diseases, and the technological advancements in diagnostics sector.

However, factors such as the short half-life of radiopharmaceuticals and its high cost are likely to restrain the market growth. Other factors restraining the market growth are side-effects of radiopharmaceuticals and strict regulations pertaining to their manufacturing.

Radiopharmaceuticals Market Segment Analysis :

The Global Radiopharmaceuticals Market, by type, has been divided into diagnostics, and therapeutic. The diagnostics segment is further segmented into SPECT radiopharmaceuticals and PET radiopharmaceuticals. SPECT radiopharmaceuticals are classified into Tc99m, I-123, and Others. PET radiopharmaceuticals segment is bifurcated into F18, C11 Choline, and Others.

The radioactive tracer (radiopharmaceutical) is given to the patient by intravenous injection, orally, or by other routes depending on the organ and the function to be studied. In developed countries about one in 50 persons are found to undergo diagnosis using radiopharmaceuticals each year. The growing importance of diagnostic radiopharmaceuticals to predict the effects of surgery and assess the changes is anticipated to drive the growth of this segment during the forecast period.

The Global Radiopharmaceuticals Market, by application segment, has been segmented into neurology, cardiology, oncology, and others. The neurology is the largest segment in the global radiopharmaceuticals market. The rising prevalence of neurological disorders is expected to drive the growth of this segment during the forecast period.

Get Sample Report Now - https://www.marketresearchfuture.com/sample_request/1650

Radiopharmaceuticals Market Regional Analysis :

The Global Radiopharmaceuticals Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas accounted for the largest share in the global radiopharmaceuticals market. The Americas is further segmented into North America and Latin America. North America is further divided into the US and Canada. Latin America consists of Mexico, Brazil, Colombia, Argentina, Chile, Peru, Uruguay, and Venezuela. The rising demand for non-invasive diagnostics and treatments and the presence of a vast patient population suffering from chronic diseases are likely to provide favorable conditions for the growth pf the market.

Europe established substantial growth in the market and anticipated to register the highest CAGR during the forecast period. Europe is segmented into Western Europe, Northern Europe, Eastern Europe, and the Rest of Europe. Rising investment for research and the presence of a vast patient pool and an increasing number of radioisotope approvals for different clinical indications are expected to drive the growth of the market.

The Asia-Pacific market for radiopharmaceuticals is further divided into Japan, China, Australia, India, South Korea, South-East Asia, New Zealand, Pakistan, and the Rest of Asia-Pacific. South-East Asia is further divided into Singapore, Malaysia, Indonesia, Thailand, Vietnam, and the Philippines. The radiopharmaceutical companies are expanding their operations in countries such as China, India, Singapore, and Russia, owing to the cost-efficiency in these regions.

Additionally, Asia-Pacific has a large pool of geriatric populations requiring invasive therapies for the treatment of the increasing cases of cardiovascular diseases, neurological diseases, and others. According to the Economic and Social Commission for Asia and the Pacific (ESCAP) in 2016, approximately 12.4% of the population in the region was 60 years or older and is projected to rise to 1.3 billion people by 2050.

The radiopharmaceuticals market in the Middle East & Africa is expected to grow due to the presence of developed countries such as Egypt, Saudi Arabia, and others. Additionally, increasing awareness about radiopharmaceuticals in the region is expected to contribute to the growth of the market.

Radiopharmaceuticals Market Key Players :

MRFR recognizes the following companies as the Key Players in the Global Radiopharmaceuticals Market— GE Healthcare, Lantheus Medical Imaging, Inc., Novartis AG, BWX Technologies, Inc., Siemens Healthineers, IRE ELiT, JSC Isotope, NTP Radioisotopes SOC Ltd, Curium, Australian Nuclear Science and Technology Organization (ANSTO), and others

Key Findings of the Study :

The Global Radiopharmaceuticals Market is estimated to grow at USD 15,060.87 million by 2025 at a CAGR of 8.10% during the assessment period.

Americas accounted for the largest share of the global market due to the presence of key market players and the rising demand for non-invasive diagnostics and treatments.

Based on the type, the diagnostics segment accounted for the largest market share of 82.9% in 2018.

Global radiopharmaceuticals market on the basis of application is dominated by neurology segment with 37.8% market share.

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/radio-pharmaceutical-market-1650

#Radiopharmaceuticals Market Research Report #Radiopharmaceuticals Market Report #Radiopharmaceuticals Market Trends

1 note · View note

pujarathod · 2 years

Text

what is Nuclear Medicine or Radiopharmaceuticals Market?

Nuclear Medicine or Radiopharmaceuticals Market size is projected to reach USD 9.52 Billion by 2028 from an estimated USD 5.70 Billion in 2021, growing at a CAGR of 7.6% globally.

The "Global Nuclear Medicine or Radiopharmaceuticals Market by Type, Application and Region - Forecast to 2028" report has been added to Introspective Market Research offering. Growth in the nuclear medicine market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices are expected to limit market growth to a certain extent.

In this report, the nuclear medicine market has been segmented based on type, application, procedure volume and region. Based on type, the nuclear medicine market is categorized into diagnostic and therapeutic nuclear medicine. The therapeutic nuclear medicine segment is further segmented into alpha emitters, beta emitters, and brachytherapy isotopes. The diagnostic nuclear medicine segment is segmented into SPECT and PET.

Key Prominent Players In The Nuclear Medicine or Radiopharmaceuticals Market:

· Actinium Pharmaceuticals Inc. (US)

· Alliance Medical (UK)

· Avid Bioservices Inc (US)

· Bayer HealthCare Pharmaceuticals (Germany)

· Bracco Diagnostics Inc. (Italy)

· Cardinal Health Inc. (US)

· GE Healthcare (US)

· Ion Beam Applications S.A (Belgium)

· Jubilant Pharma (India)

· Lantheus Medical Imaging Inc. (US)

· Medi-Radiopharma Ltd (Hungary)

· Nordion Inc. (Canada)

· Novartis/Advanced Accelerator Applications (France)

· Positron Corporation (US)

· Radiopharm Theranostics Ltd. (US)

Know More About The Global Trends Impacting The Future, Download A PDF Sample@:https://www.introspectivemarketresearch.com/request/15924

Market segmentation

The Nuclear Medicine or Radiopharmaceuticals market is segmented by type and application. Growth between segments over the period 2022-2028 provides accurate calculations and forecasts of revenue by type and application in terms of volume and value. This analysis can help you expand your business by targeting eligible niches.

Nuclear Medicine or Radiopharmaceuticals Market Segment by Types, Estimates, and Forecast by 2028

Diagnostic,Therapeutic,Research

Nuclear Medicine or Radiopharmaceuticals Market Segment by Applications, Estimates, and Forecast by 2028

Oncology,Thyroid,Cardiology,Neurology and Others

Regional Analysis for COVID-19 Outbreak-Global Nuclear Medicine or Radiopharmaceuticals Market:

APAC (Japan, China, South Korea, Australia, India, and Rest of APAC)

Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)

North America (U.S., Canada, and Mexico)

South America (Brazil, Chile, Argentina, Rest of South America)

MEA (Saudi Arabia, UAE, South Africa)

We Offer Discount on The Nuclear Medicine or Radiopharmaceuticals Market Report @: https://www.introspectivemarketresearch.com/discount/15924

Industry experts have identified key factors influencing the pace of development of the Nuclear Medicine or Radiopharmaceuticals industry, including various opportunities and gaps. A thorough analysis of the Nuclear Medicine or Radiopharmaceuticals market for the growth trends of each category makes the overall study interesting. When studying the market, researchers also dig deep into their future prospects and their contribution to the industry. Additionally, the research report evaluated the market key players and features, such as capacity utilization rate comprised of revenue.

Nuclear Medicine or Radiopharmaceuticals Report provides insights into the following queries:

1.Market growth rate and growth momentum of Nuclear Medicine or Radiopharmaceuticals market for the period 2022-2028 2. The estimated size of the Nuclear Medicine or Radiopharmaceuticals market for the period 2022-2028 4. Sales (volume), revenue, and value analysis by regions of Nuclear Medicine or Radiopharmaceuticals market 5. The associated market risk, opportunity, and market overview of the Nuclear Medicine or Radiopharmaceuticals market 6. Major distributors, dealers, end-users, and traders of the Nuclear Medicine or Radiopharmaceuticals market?

Make An Inquiry For Report Customization (Must Use Business Contact Details For High Preference):https://www.introspectivemarketresearch.com/inquiry/15924

This study conducts a SWOT analysis to evaluate the strengths and weaknesses of key players in the Nuclear Medicine or Radiopharmaceuticals market. Additionally, the report performs a complex inspection of drivers and restraints operating in the market. The report also evaluates the observed trends in the parent market along with macroeconomic indicators, dominant factors and market attractiveness in relation to other segments. The report forecasts the impact of various industry aspects on the Nuclear Medicine or Radiopharmaceuticals market segments and regions.

Key Points Covered in Radiopharmaceuticals Market Study

· Market estimates and forecast 2022-2028

· Key drivers and restraints impacting market growth

· Segment-wise, Country-wise, and Region-wise Analysis

· Competition Mapping and Benchmarking

· Brand share and Market Share Analysis

· Key Radioisotope Innovations and Regulatory Climate

· COVID-19 Impact on Radiopharmaceuticals market and How to Navigate

· Recommendation on Key Winning Strategies

#Nuclear Medicine or Radiopharmaceuticals Market Nuclear Medicine or Radiopharmaceuticals Market Size Nuclear Medicine or Radiopharmaceutical

0 notes

zaras2424 · 3 years

Text

Outlook of Pet Cancer Therapeutics Market - Explore the 2021 to 2030 Industry Analysis & Forecast

The most common cancer sort among the dogs are completely different varieties of malignant neoplastic disease, showing enlargement of external liquid body substance nodes. The Veterinary Cancer Society rumored that cancer is that the leading reason for death for 47.5% of the dogs WHO are aged over 10 and thirty-two of the cats. Early detection and adequate treatment are the simplest thanks to manage cancer in pets. Increasing investment for analysis and development for brand new diagnostic strategies and coverings for cancer management can drive the expansion of pet cancer medical specialty market. Global Pet Cancer Therapeutics Market report that offers meticulous investigation of current situation of the market size, share, demand, growth, trends, firms active within the business and forecasts for the approaching years.

Access the Full Report @ https://www.absolutemarketsinsights.com/reports/Pet-Cancer-Therapeutics-Market-2019-2027-160

The Pet Cancer Therapeutics market participants include AdvaVet, Advaxis Inc., Amgen Inc., Aratana Therapeutics, Inc., Boehringer Ingelheim International GmbH, CanFel Therapeutics, ELIAS Animal Health, Fetch Pharma, Genentech, Innogenics, Karyopharm Therapeutics, Kindred Biosciences, Morphogenesis, Inc., NIPPON ZENYAKU KOGYO CO., LTD., Oasmia Pharmaceutical AB, PetLife Pharmaceuticals, Inc., Pharmaust., Phibro Animal Health Corporation, Regeneus Ltd, Rhizen Pharmaceuticals S.A., Torigen Pharmaceutical Inc., Vaccibody, VetDC, Virbac., Zoetis Services LLC amongst others.

Dogs having malignant cancers usually cannot be treated by therapies like therapy, surgeries and therapy. Oral melanoma (OMM) could be an extremely invasive cancer among dogs. Pharmaceutical corporations finance in medical specialty have introduced a sturdy pipeline of drug for the treatment of extremely current conditions in pets like cancer and malignant melanoma. Personal and government organizations like Veterinary Cancer Society, Petco Foundation and Animal Cancer foundation are operating along with pharmaceutical corporations to formulate novel drug Pet Cancer Therapeutics Market which is able to absolutely impact the business growth.

Key Questions Answered in Report:

What is major factor which lead this market to next level? • What will the market Demand and what will be Growth? • What are the latest opportunities to Pet Cancer Therapeutics market in future? • What are the strengths of the key players? • What are the key of Pet Cancer Therapeutics market?

Pet Cancer Therapeutics Market:

By Animal Type

Dogs

Cats

Horses

Others

By Cancer Type

Mast Cell Cancer

Lymphoma

Melanoma

Mammary

Squamous Cell Cancer

Others

By Route of Administration

Oral

Intravenous

Others

By Therapy Type

Chemotherapy

Targeted Therapy

Combination Therapy

Immunotherapy

By Geography

North America [U.S., Canada, Mexico]

Europe [Germany, UK, France, Italy, Rest of Europe]

Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]

South America [Brazil, Argentina, Rest of Latin America]

Middle East & Africa [GCC, North Africa, South Africa, Rest of the Middle East and Africa]

Contact Us: Company: Absolute Markets Insights Email id: [email protected] Phone: +91-740-024-2424 Contact Name: Shreyas Tanna Website: https://www.absolutemarketsinsights.com

0 notes

topnewscenter · 3 years

Text

Musculoskeletal Oncology Therapeutics Market Research Report 2021 - Industry Size, Share, Demands, Regional Analysis & Estimations Till 2027

The Musculoskeletal Oncology Therapeutics Market Report, in its latest update, highlights the significant impacts and the recent strategical changes under the present socio-economic scenario. The Musculoskeletal Oncology Therapeutics industry growth avenues are deeply supported by exhaustive research by the top analysts of the industry. The report starts with the executive summary, followed by a value chain and marketing channels study. The report then estimates the CAGR and market revenue of the global and regional segments.

Base Year: 2020

Estimated Year: 2021

Forecast Till: 2027

The report classifies the market into different segments based on type and product. These segments are studied in detail, incorporating the market estimates and forecasts at regional and country levels. The segment analysis is helpful in understanding the growth areas and potential opportunities of the market.

Get | Download FREE Sample Report of Global Musculoskeletal Oncology Therapeutics Market @ https://www.decisiondatabases.com/contact/download-sample-6309

A special section is dedicated to the analysis of the impact of the COVID-19 pandemic on the growth of the Musculoskeletal Oncology Therapeutics market. The impact is closely studied in terms of production, import, export, and supply.

The report covers the complete competitive landscape of the Worldwide Musculoskeletal Oncology Therapeutics market with company profiles of key players such as:

Stryker Corporation

Accentus Inc.

Roche Diagnostics

Amgen Inc.

Novartis AG, Biogen

GlaxoSmithKline

Sanofi S.A.

Pfizer Inc.

Want to add more Company Profiles to the Report? Write your Customized Requirements to us @ https://www.decisiondatabases.com/contact/get-custom-research-6309

Musculoskeletal Oncology Therapeutics Market Analysis by Diagnosis:

X- Ray

Magnetic Resonance Imaging (MRI) Scan

Computed Tomography (CT) Scan

Positron Emission Tomography (PET) Scan

Biopsy

Musculoskeletal Oncology Therapeutics Market Analysis by Treatment:

Surgery

Amputation

Limb Salvage Surgery

Reconstructive Surgery

Chemotherapy

Radiation Therapy

Immunotherapy

Targeted Therapy

Musculoskeletal Oncology Therapeutics Market Analysis by End – User:

Multispecialty Hospitals

Cancer Research Institutes

Diagnostic Centers

Musculoskeletal Oncology Therapeutics Market Analysis by Geography:

North America (USA, Canada, and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Australia, South-East Asia, Rest of Asia-Pacific)

Latin America (Brazil, Argentina, Peru, Chile, Rest of Latin America)

The Middle East and Africa (Saudi Arabia, UAE, Israel, South Africa, Rest of the Middle East and Africa)

Key questions answered in the report:

What is the expected growth of the Musculoskeletal Oncology Therapeutics market between 2022 to 2027?

Which application and type segment holds the maximum share in the Global Musculoskeletal Oncology Therapeutics market?

Which regional Musculoskeletal Oncology Therapeutics market shows the highest growth CAGR between 2022 to 2027?

What are the opportunities and challenges currently faced by the Musculoskeletal Oncology Therapeutics market?

Who are the leading market players and what are their Strengths, Weakness, Opportunities, and Threats (SWOT)?

What business strategies are the competitors considering to stay in the Musculoskeletal Oncology Therapeutics market?

Purchase the Complete Global Musculoskeletal Oncology Therapeutics Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-6309

About Us:

DecisionDatabases.com is a global business research report provider, enriching decision-makers, and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research reports, customized research reports, company profiles, and industry databases across multiple domains. Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise, and meaningful data at a lightning speed.

For more details: DecisionDatabases.com E-Mail: [email protected] Phone: +91 90 28 057900 Web: https://www.decisiondatabases.com/

#Musculoskeletal Oncology Therapeutics Market #Musculoskeletal Oncology Therapeutics Market Report #Musculoskeletal Oncology Therapeutics Market Size

0 notes

healthcare-market · 3 years

Text

Latest TMR Report Explores Impact of COVID-19 Outbreak on Brain Tumor Diagnosis and Treatments Market

The worldwide brain tumor diagnosis and treatments market has a strong seller landscape and features an escalated challenge, says by Transparency Market Research. This is transcendently owing to the presence of various new participants are attempting to wander into the worldwide brain tumor diagnosis and treatments market. There are likewise developed players in the business who are exceling in the worldwide brain tumor diagnosis and treatments markets, for example, Novartis, Immunocellular Therapeutics, NOVOCURE, Delmar Pharmaceuticals Inc., and Moleculin Biotech.

For example, in 2015, NICO reported its coordinated effort with Hitachi Aloka Medical to improve representation of hard to achieve brain tumors. January 2018: iTeos Therapeutics recovered rights to its Phase I brain malignant growth sedate from Pfizer, and plans to proceed with oncology advancement. December 2017: Diffusion Pharmaceuticals (DFFN) propelled Phase III preliminary for Glioblastoma

Request a PDF Sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=25247

As indicated by TMR investigators, the worldwide brain tumor diagnosis and treatments market was esteemed at US$406.0 mn in 2016 and is anticipated to develop at a noteworthy 8.5% CAGR in the gauge time of 2017 to 2025 and reach US$840.7 mn before the finish of 2025. Based on diagnosis type, the worldwide brain tumor diagnosis and treatments market has been bifurcated into CT-Scan, MRI, Molecular Testing, PET-CT Scan, and EEG, with the previous representing over 35% offer of worldwide market in 2016. It has been noticed that CT-Scan remain the most favored decision of brain malignant growth diagnosis, attributable to their capacity to successfully separate between bone masses and expand delicate tissues, other than offering the alternative to click 3D pictures in an arrangement at different edge.

North America overwhelms the worldwide market share inferable from the nearness of positive repayment approaches and propelled medicinal services foundation. APAC districts are worthwhile markets for the development of brain tumor growth diagnostics. This is attributable to the existence of overwhelming neglected needs in the rising economies, for example, China and Japan.

Request for Analysis of COVID19 Impact on Brain Tumor Diagnosis and Treatments Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=25247

Prevalence of Brain Cancer Driving Demand

Expanding predominance of brain malignant growth, advancements in medication conveyance to brain disease cells, and expanding market for the treatment of brain disease related side effects are a portion of the key components enlarging the demand in the worldwide brain tumor diagnosis and treatments market. Notwithstanding these components, the human services segment is seeing expanding open private organizations (PPPs), which is propelling the symptomatic imaging and radiology administrations. The approach of advances, for example, Positron Emission Tomography (PET), Sodium Magnetic Resonance Imaging (23Na MRI), and Chemical Exchange Saturation Transfer (CEST) are currently every now and again utilized to distinguish the reaction of brain tumors in multicenter clinical preliminary settings.

The TMR report takes note of that these innovations can possibly expand MRI past anatomical imaging by empowering data on physiology and cell digestion. These headways by and large will expand the proficiency of diagnosis, and along these lines help to the market extension amid the conjecture time frame. Besides, progressing research in sub-atomic diagnostics to distinguish quality changes related with threat and understand the cell science at cell dimension of danger will likewise support the development of the market for brain tumor diagnosis and treatments.

Buy now Brain Tumor Diagnosis and Treatments Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=25247&ltype=S

High Cost of Treatment Hindering Growth

Then again, particularly mind-boggling expense of treatment is the most glaring restriction over the best possible flourishing of the worldwide brain tumor diagnosis and treatments market. Cost factors are limiting the development of the market in the rising nations, in spite of them improving their medicinal services framework. Accessibility of just a couple of brain malignant growth explicit medications and expanding utilization of generics in chemotherapy are other two difficulties looked by the worldwide market for brain tumor diagnosis and treatments.

The study presented here is based on a Transparency Market Research report titled “Brain Tumor Diagnosis and Treatments Market (Product Type - Primary Brain Tumor (Meningioma, Gliomas, Astrocytomas, and Pituitary Tumors) and Secondary Brain Tumor; Diagnosis Type - CT Scan, MRI, PET-CT Scan, Molecular Testing, and EEG; Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy, and Immunotherapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025.”

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/solutions-offered-by-software-product-services-companies-to-drive-telemedicine-market-to-us-109-43-bn-by-2027--says-tmr-301362599.html

https://www.prnewswire.com/news-releases/adoption-of-rpa-technology-to-outsource-manual-repetitive-tasks-to-drive-life-sciences-bpo-market-tmr-insights-301345998.html

https://www.prnewswire.co.uk/news-releases/increase-in-demand-for-treatment-of-venous-thromboembolism-to-boost-global-unfractionated-heparin-market-says-tmr-897429570.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com

0 notes

mukongs · 3 years

Text

Overview of new technologies in tumor immunotherapy: cell therapy continues to heat up, and oncolytic bacteria reappear

According to official data from the Who's International Agency for Research on Cancer (IARC), there were 19.29 million new cancer cases and 9.96 million deaths worldwide in 2020, both figures representing further increases from 2019. With the increasing incidence and mortality of cancer worldwide, it is becoming more and more urgent to find new technologies and methods for effective treatment of cancer.

In addition to traditional treatment methods such as surgery, radiotherapy and chemotherapy, continuously innovative immunotherapy has gradually become an important development direction in the field of global cancer treatment. In recent years, more and more new therapies have emerged in subdivided fields, promoting the development and expansion of tumor immunotherapy industry.

Today, we take a look at some of the world's most groundbreaking cancer immunotherapies and see which new life science technologies are bringing hope and hope to millions of cancer patients around the world.

CAR T/TCR-T cell therapy

ChimericAntigen Receptor t-cell (ChimericAntigen Receptor t-cell) is the full name of CAR T Cell. CAR T cell immunotherapy (CAR T cell immunotherapy) is a new treatment method for tumor and cancer. It extracted immune T cells from the patients first, and then using genetic engineering technology, writing can make T cells in vitro, identify specific gene fragment of tumor cells and kill tumor cells, and this kind of CAR - T cells in the lab, a lot of training, and then after the expansion of the "enhanced" immune T cells back to patient treatment.

Since Rosenberg first proposed genetically engineered T cell technology in 1986, CAR-T therapy has gone through 35 years. Gene therapy represented by CAR-T cell therapy was rated as "breakthrough therapy" by FDA and accelerated to become a clinical reality. In 2017, the U.S. Food and Drug Administration (FDA) approved ctL-019 (Kymriah) for the treatment of b-cell acute lymphoblastic leukemia (AML) that is refractory or relapsed after at least second-line therapy.

Many domestic biotechnology companies, such as Fuxing Kitt, Yao Ming Junol, Keji Pharmaceutical, Chuanqi Bio and Yongtai Bio, have also entered the competition track of CAR T cell therapy. In June this year, Fosun Kitt's CAR-T product Aquilenxel was officially launched in China. On August 9, the latest public information of Drug Evaluation Center (CDE) of China's State Food and Drug Administration showed that Aquilenxel injection declared by Fosun Kitt was included in the breakthrough treatment drug program. The proposed application for the treatment of relapsed or refractory indolent non-Hodgkin's lymphoma after second-line or higher systemic therapy represents an important step forward in the development of the domestic CAR T cell industry.

Both TCR-T cells and CAR T cells are genetically engineered T cells. Tcr-t cells can recognize tumor-specific antigens from cell membrane surface or intracellular sources, and TCR-t cells targeting NY-ESO-1 have demonstrated good safety and efficacy in clinical trials of refractory and recurrent melanoma, synoviosarcoma, multiple myeloma and lung cancer at home and abroad. T cell immunotherapy is the most likely to achieve a breakthrough in the treatment of solid tumors.

Recently, TCR-T cell therapy continues to heat up, and the market is promising. T-knife Therapeutics, Inc., today announced the completion of a $110 million Series B funding round to bring its TCR-T pipeline into the clinic, expand its scientific team and increase production capacity, according to public information.

Oncolytic virus therapy

Oncolytic virus is a natural or genetically engineered virus that can selectively replicate in tumor tissue and then infect and kill tumor cells or cause lysis of tumor cells, but has no killing effect on normal tissues. Oncolytic therapy is gaining increasing attention from cancer patients and industry markets due to its ability to specifically replicate within tumor cells and cause lysis of tumor cells without affecting normal cells.

In 2004, the first oncolytic virus product Rigvir (ECHO-7 virus) was approved in Latvia for the treatment of melanoma and other cancers; In the following year, China's first oncolytic drug Ankerin (recombinant human adenovirus type 5) was also approved for marketing, which was used for the treatment of primary, clinically advanced and recurrent head and neck tumors and showed very good efficacy in the treatment of advanced nasopharyngeal cancer and bladder cancer. In 2015, THE US FDA approved Amgen's oncolytic drug T-VEC (herpes simplex virus) for marketing for the first time, for the treatment of advanced melanoma, so far the development of oncolytic therapy in the world gradually mature.

In June this year, Daiichi Sankyo announced that its oncolytic virus product Delytact (Teserpaturev /G47∆) was approved in Japan by the Ministry of Health, Labour and Welfare (MHLW) for the treatment of malignant glioma, the fourth oncolytic virus product approved worldwide. At the same time, astrazeneca, Johnson & Johnson, Arna& Pharma and other major pharmaceutical companies began to cluster oncolytic virus distribution, and have entered the oncolytic virus track by adding corresponding departments or acquiring other small and medium-sized pharmaceutical companies.

In terms of domestic enterprises, Hengrui Pharmaceutical, Kanghong Biological, Lepu Medical and so on have a layout in this field, and the development progress of some products has been very advanced. And the current focus on soluble tumor virus therapy research also micro drug, is dedicated to the research and development of a new generation of genetically modified herpes soluble tumor virus with used in the treatment of cancer, and in succession recently announced that its clinical trials of two soluble tumor virus product application were approved, soluble tumor virus therapy at home and abroad to track competition was in full swing, a lively group.

Oncolytic bacterial therapy

Soluble tumor viruses, bacteria and soluble tumor is a tumor immunotherapy soluble tumor carrier category is emerging in the field of therapy, its principle is to bacteria through genetic programming technique for attenuated "good bacteria", and can be used as a carrier to carry drugs targeting tumors and the tumor internal release drugs kill cancer, exert its "soluble tumor" effect.

The idea of using bacteria to fight cancer and treat cancer has a long history of experimental research, but there are very few drugs that have really entered the stage of clinical research and have been on the market. At present, the only drug on the market is therapeutic BCG, which is mainly used for postoperative perfusion of bladder cancer. In 2014, The listeria vector project -- CRS-207 combined with GVAX in the treatment of pancreatic cancer, a collaboration between Johnson & Johnson and Aduro, a biotechnology company, was recognized as a breakthrough therapy by FDA in the United States. However, due to unsatisfactory experimental results, Aduro finally gave up the promotion plan of CRS-207 project.

Until The successful development of the world's first oncolytic bacterial vector by Hong Kong Pharmaceutical Oncolytic Biotechnology Co., LTD. (a domestic biotechnology company focusing on the development of innovative drugs in the field of tumor immunotherapy), it marked another key progress of oncolytic bacterial therapy.

Data show that the RESEARCH and development team of Hong Kong Pharmaceutical Oncolytic Biotechnology Co., Ltd. experienced more than 10 years of research and development cycle, based on synthetic biology, invented a genetically programmed salmonella, and named it YB1; This oncolytic bacterium YB1 can be used as a carrier to deliver therapeutic drugs including antibodies, mRNA, protein drugs, etc., targeting the tumor and releasing drugs internally to attack the tumor and cause tumor dissolution.

The port drug dissolved tumor biological pharmaceutical products currently has completed its soluble tumor bacteria YB1 pet primary cancer therapy in clinical trials, bacteria and has begun to push its soluble tumor immunotherapy of human clinical trials, and the layout of the application of YB1 multiple product line, as to when to have a more mature listed products can actually benefit cancer patients is still unknown.

From the perspective of the world, many international pharmaceutical giants have also begun to flood into the super emerging race track of oncolytic bacteria, including Roche, Merck, Pfizer, Bristol-Myers Squibb and other big pharmaceutical companies have laid out the pipeline of oncolytic bacteria related products. In the future, this subdivision field is bound to be more exciting competition.

summary

Although human has not been completely conquer cancer, but with the development of life science and the progress of new medical technology, the emergence of more and more new cancer treatment technology has let the cancer patients see the hope and light, we are looking forward to the innovative therapy to achieve more breakthroughs, make more patients benefit.

CAR /TCR-T cell therapy, oncolytic virus, oncolytic bacteria, etc. have been running in their respective fields. Tumor immunotherapy is in the ascendant. When will the next "promising star" rise? We'll see!

0 notes

ellinapark · 2 years

Text

Radiopharmaceuticals in Nuclear Medicine Market to Eyewitness Massive Growth by 2027

Cardinal Health (United States)

GE Healthcare (United States)

Curium (France)

Lantheus Medical Imaging (United States)

Bayer AG (Germany)

Bracco Imaging (Italy)

EczacÃ½baÃ¾Ã½-Monrol Nuclear Products (Turkey)

Nordion (Canada)

Advanced Accelerator Applications (France)

NTP Radioisotopes (South Africa)

The Radiopharmaceuticals in Nuclear Medicine Market segments and Market Data Break Down 24360

Market Challenges: Hospital budget cuts and high equipment costs

Market Opportunities: Use of radiopharmaceuticals in neurological applications

Highlights of Influencing Drivers: Rising incidence as well as prevalence of target conditions

Huge Development of alpha-radioimmunotherapy-based targeted cancer treatments

Presented By

AMA Research & Media LLP

0 notes

adityarana1687-blog · 3 years

Text

Optical Preclinical Imaging Market Is Projected To Reach USD 543.0 Million By 2025

The global optical preclinical imaging market size is expected to reach USD 543.0 million by the end of 2027, expanding at a CAGR of 3.3%, according to a new report by Grand View Research, Inc. Increasing number of preclinical studies aimed to study and develop various effective therapeutics for different diseases is a major factor boosting the adoption of optical preclinical imaging systems.

For instance, in December 2018, Bugworks Research, a drug discovery startup based in India, received US$ 3 million grant from CARB-X, a Boston-based organization. The grant was offered to support the development of preclinical trail for novel molecules to fight antimicrobial resistance. Moreover, various researchers are engaged in finding novel ways to increase the reproducibility and robustness of preclinical cancer research with an aim to reduce the failure rate of oncology clinical trials. Optical imaging also allows cost-effective and high-throughput animal study as compared to small animal molecular imaging technologies, including PET and MRI systems.

To request a sample copy or view summary of this report, click the link below: www.grandviewresearch.com/industry-analysis/optical-preclinical-imaging-market

Further key findings from the study suggest:

North America accounted for the largest share in 2019 owing to well-established research infrastructure, adoption of guidelines for preclinical research, product approvals, and higher number of drug development projects

Based on product type, in the device segment, bioluminescence captured the largest optical preclinical imaging market share in 2019 owing to high sensitivity and broad dynamic range as compared to other techniques for imaging animals used in various studies

The bioluminescence segment is expected to witness significant growth over the forecast period due to increasing adoption of bioluminescence technology to visualize and study disease processes in laboratory animals

By end use, the pharma and biotech companies segment accounted for the largest optical preclinical imaging market share in 2019 owing to increasing number of candidates in drug development studies and increasing focus on research and development for drug development and innovation

The research institutes segment is expected to witness the fastest growth during the forecast period owing to rising adoption of advanced optical imaging systems in the research institutes

Leading players operating in the market for optical preclinical imaging include Bruker; Perkin Elmer, Inc.; MR Solutions; BioTek Instruments, Inc.; Milabs B.V.; Fujifilm Holdings Corporation; Magnetic Insight, Inc.; MBF Bioscience; and Mediso Ltd.

Grand View Research has segmented the global optical preclinical imaging market on the basis of product type, end use, and region:

Optical Preclinical Imaging Product Type Outlook (Revenue, USD Million, 2016 - 2027)

Device

Consumables

Software

Fluorescence

Bioluminescence

Fluorescence

Bioluminescence

Green fluorescent proteins

Red fluorescent proteins

Infrared dyes

Others

Luciferins

Proluciferins

Coelenterazine

Others

Optical Preclinical Imaging End-use Outlook (Revenue, USD Million, 2016 - 2027)

Pharma and Biotech Companies

Research Institutes

Others

Optical Preclinical Imaging Regional Outlook (Revenue, USD Million, 2016 - 2027)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

U.S.

Canada

U.K.

Germany

France

Italy

Spain

Russia

Japan

China

India

Malaysia

Thailand

South Korea

Brazil

Mexico

Argentina

Columbia

South Africa

Saudi Arabia

UAE

Qatar

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

#Optical Preclinical Imaging Market

0 notes

market-insights-dbmr · 3 years

Text

Pet Cancer Therapeutics Industry 2021: Seeking Excellent Growth||Research By Data Bridge Market Research

Pet cancer therapeutics refers to the type of new anti-cancer drugs containing capability to lessen the effect of cancerous cell.

Global Pet Cancer Therapeutics Market, By Therapy (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Combination Therapy, Others), Medicine Type (Chemotherapy Drugs, Vaccines), Route of Administration (Parenteral, Oral, Others), Cancer Type (Melanoma, Mast Cell Cancer, Lymphoma, Mammary and Squamous Cell Cancer, Others), Species Type (Cat, Dog, Others), End User (Veterinary Hospitals and Clinical Pharmacies, Retail Pharmacies, Online Pharmacies, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.

Get Sample Copy Of This Study @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pet-cancer-therapeutics-market

Pet cancer therapeutics market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to USD 438.76 million by 2028 and will grow at a CAGR of 9.10% in the above mentioned forecast period.

The major players covered in the pet cancer therapeutics market report are AB Science, Aratana Therapeutics, Inc., CanFel Therapeutics, Nippon Zenyaku Kogyo Co., Ltd., Morphogenesis, Inc., Rhizen Pharmaceuticals AG, Virbac, Pfizer Inc., VetDC, Boehinger Ingelheim International GmbH, Karyopharm, Elanco, VETCO, ELIAS Animal Health, Oasmia Pharmaceutical AB, Regeneus Ltd., Torigen Pharmaceuticals Inc., and Zoetis among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Our report offers the following data from 2021 to 2028:–

– Pet cancer therapeutics Market share assessments for the regional and country level segments.

– Market share analysis of the top industry players.

– Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets.

– Pet cancer therapeutics Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations).

– Strategic recommendations in key business segments based on the market estimations.

– Competitive landscaping mapping the key common trends.

– Company profiling with detailed strategies, financials, and recent developments.

– Pet cancer therapeutics Industry Supply chain trends mapping the latest technological advancements.

Pet Cancer Therapeutics Market Scenario

According to Data Bridge Market Research, the markets for the pet cancer therapeutics market is escalating due to the rise in the awareness of pet owners regarding pet diseases and increase in the trend towards new product development. Additionally, increase in trend of pet adoption, such as dogs and cats owing to the improved economic status of people and increase in research and development expenditure positively affect the pet cancer therapeutics market.

Furthermore, rise in pet healthcare expenditure extends profitable opportunities to the market players.

Now the question is, which are the other regions that renewable solvents market is targeting? Data Bridge Market Research has estimated North America dominates due to the rapid increase in the prevalence of pet cancer, and well-established health care infrastructure within the region. Asia-Pacific is expected to witness significant growth in the forecast period of 2021 to 2028 owning to the growing incidence of pet cancer in the region.

Key Pointers Covered in the Pet Cancer Therapeutics Market Industry Trends and Forecast to 2028

· Market Size

· Market New Sales Volumes

· Market Replacement Sales Volumes

· Market By Brands

· Market Procedure Volumes

· Market Product Price Analysis

· Market Regulatory Framework and Changes

· Market Shares in Different Regions

· Recent Developments for Market Competitors

· Market Upcoming Applications

· Market Innovators Study

To know more about the study, please click on the below mentioned link, https://www.databridgemarketresearch.com/reports/global-pet-cancer-therapeutics-market

0 notes

zaras2424 · 3 years

Text

What is Trending in Pet Cancer Therapeutics Market? Strategies to Boost Business in Near Years?

The most common cancer sort among the dogs are completely different varieties of malignant neoplastic disease, showing enlargement of external liquid body substance nodes. The Veterinary Cancer Society rumored that cancer is that the leading reason for death for 47.5% of the dogs WHO are aged over 10 and thirty-two of the cats. Early detection and adequate treatment are the simplest thanks to manage cancer in pets. Increasing investment for analysis and development for brand new diagnostic strategies and coverings for cancer management can drive the expansion of pet cancer medical specialty market. Global Pet Cancer Therapeutics Market Size report that offers meticulous investigation of current situation of the market size, share, demand, growth, trends, firms active within the business and forecasts for the approaching years.

Access the Full Report @ https://www.absolutemarketsinsights.com/reports/Pet-Cancer-Therapeutics-Market-2019-2027-160

The Pet Cancer Therapeutics Market Size participants include AdvaVet, Advaxis Inc., Amgen Inc., Aratana Therapeutics, Inc., Boehringer Ingelheim International GmbH, CanFel Therapeutics, ELIAS Animal Health, Fetch Pharma, Genentech, Innogenics, Karyopharm Therapeutics, Kindred Biosciences, Morphogenesis, Inc., NIPPON ZENYAKU KOGYO CO., LTD., Oasmia Pharmaceutical AB, PetLife Pharmaceuticals, Inc., Pharmaust., Phibro Animal Health Corporation, Regeneus Ltd, Rhizen Pharmaceuticals S.A., Torigen Pharmaceutical Inc., Vaccibody, VetDC, Virbac., Zoetis Services LLC amongst others.

Dogs having malignant cancers usually cannot be treated by therapies like therapy, surgeries and therapy. Oral melanoma (OMM) could be an extremely invasive cancer among dogs. Pharmaceutical corporations finance in medical specialty have introduced a sturdy pipeline of drug for the treatment of extremely current conditions in pets like cancer and malignant melanoma. Personal and government organizations like Veterinary Cancer Society, Petco Foundation and Animal Cancer foundation are operating along with pharmaceutical corporations to formulate novel drug Pet Cancer Therapeutics Market Size which is able to absolutely impact the business growth.

Key Questions Answered in Report:

What is major factor which lead this market to next level?

What will the market Demand and what will be Growth?

What are the latest opportunities to Pet Cancer Therapeutics Market Size in future?

What are the strengths of the key players?

What are the key of Pet Cancer Therapeutics market?

Pet Cancer Therapeutics Market:

By Animal Type

Dogs

Cats

Horses

Others

By Cancer Type

Mast Cell Cancer

Lymphoma

Melanoma

Mammary

Squamous Cell Cancer

Others

By Route of Administration

Oral

Intravenous

Others

By Therapy Type

Chemotherapy

Targeted Therapy

Combination Therapy

Immunotherapy

By Geography

North America [U.S., Canada, Mexico]

Europe [Germany, UK, France, Italy, Rest of Europe]

Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]

South America [Brazil, Argentina, Rest of Latin America]

Middle East & Africa [GCC, North Africa, South Africa, Rest of the Middle East and Africa]

Contact Us: Company: Absolute Markets Insights Email id: [email protected] Phone: +91-740-024-2424 Contact Name: Shreyas Tanna Website: https://www.absolutemarketsinsights.com

0 notes

jesse-pinkman123 · 3 years

Text

Theranostics Market Size Share Trends Forecast Opportunity Analysis 2026

Global Theranostics Market Drivers:-

Development of novel companion diagnostic tests to be used with available treatment options is expected to boost the global Theranostics Market growth over the forecast period. Leading manufacturers are engaged in introduction of novel companion diagnostic tests in market. For instance, Illumina, Inc. announced launch of the U.S. Food & Drug Administration (FDA) approved extended RAS panel for identification of patients eligible for treatment of metastatic colorectal cancer with Vectibix (panitumumab) in 2017.

Increasing adoption of companion diagnostic tests by laboratories is further expected to foster global theranostics market growth over the forecast period. BloodCenter of Wisconsin's Diagnostic Laboratories started offering Abbott RealTime IDH1 assay for patients with acute myeloid leukemia (AML) in July 2018. Moreover, Cancer Genetics, Inc. started offering FDA approved companion diagnostic Thermo Fisher Scientific's Oncomine Dx Target - the first Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) test in 2017. Laboratory Corporation of America Holdings launched OmniSeq Advance in partnership with OmniSeq for tumor cancers in June 2018.

Partnerships and collaborations by leading manufacturers to develop innovative companion diagnostics is expected to foster global theranostics market growth over the forecast period. For instance, Foundation Medicine, Inc. and Pfizer, Inc. entered into a partnership for development, regulatory support, and commercialization of companion diagnostics (CDx) in January 2018. Moreover, Qiagen, Inc., and Freenome partnered in June 2018, to accelerate the development and commercialization of Next-Generation Sequencing (NGS) tests to enable precision medicine in cancer treatment.

Pierre Fabre and Roche have been working on development of a robust prototype immunohistochemistry assay as a future companion diagnostic test for W0101 (the drug candidate which they are developing together) and extended this collaboration in May 2018. Abbott Laboratories, Inc. collaborated with Celgene Corporation, and Agios Pharmaceuticals, to develop diagnostic tests on Abbott’s m2000 RealTime system that identifies certain genomic mutations associated with acute myeloid leukemia (AML) in 2016. These factors are expected to support global theranostics market growth over the forecast period.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2043

Theranostics involves combination of targeted diagnostic tests with targeted therapy. It is also known as companion diagnostics, integrated medicine, Dx/Rx partnering, and pharmacodiagnostics. Implementation of theranostics into the patient care plan (in case of selected diseases for which diagnostic tests are available along with respective therapy) may turn into personalized therapy, which could further improve medical outcomes.

Theranostics include use of specific diagnostic test, which shows a particular molecular target on a tumor or any other disease causing agent. Any disease pathophysiology involves specific biological pathways, which are targeted with the help of diagnostic tests. Diagnostic images of the particular molecule then identifies presence of the specific mutation or receptors (in case of cancer), which can be targeted with the help of therapeutic agents. This approach avoids trial and error treatment and could be used to offer patient specific treatment at the right time. Accurate dose calibration and precisely targeted approach could highly be useful in management of chronic diseases such as cancer.

For instance, neuro endocrine tumors can be diagnosed to assess extent of disease via PET-CT (Positron Emission Tomography – Computer Tomography) using Ga-68 DOTATOC (a radioactive positron emitter). Ga-68 targets somatostatin receptor (SSTR2) on the tumor cell membrane, and is injected through vein, which travels and binds to the SSTR2 indication the presence of tumor on PET scan. Furthermore, Ga-68 can be replaced by a therapeutic agent to target the tumor.

However, improperly defined regulations for these tests coupled with inadequate reimbursement facilities are expected to hamper growth of the global theranostics market over the forecast period.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/theranostics-market-2043

Global Theranostics Market Regional Insights:-

North America is expected to witness significant growth in the global theranostics market over the forecast period. Presence of leading manufacturers, collaborations, robust research, and development activities, and increasing adoption of companion diagnostics is expected to support global theranostics market growth over the forecast period. Biocartis Group NV and Amgen, Inc. partnered to develop companion diagnostic test for Amgen's drug Vectibix (panitumumab) in 2017. For instance, Genome Canada launched a national initiative for clinical implementation of precision health in June 2018, which would ultimately impact global theranostics market growth over the forecast period.

Asia Pacific theranostics market is expected to witness significant growth over the forecast period, owing to collaborations in the region by global organizations and increasing awareness regarding companion diagnostics. For instance, Qiagen collaborated with Japan based clinical lab testing company, SRL, Inc. for introduction of new companion diagnostics with new drug approvals in August 2018.

Key players of Global Theranostics Market:-

Key players operating in the global theranostics market include Thermo Fisher Scientific, Inc., Beckman Coulter, Inc., Focus Diagnostics, AmeriPath, Inc., Illumina, Inc., F.Hoffmann LA-Roche Ltd., Qiagen NV, Myriad Genetics, Inc., Agilent Technologies, Abbott Laboratories, Foundation Medicine, Inc., and Oxford Cancer Biomarkers, Ltd.

Key Development:-

In 2018, THERADIAG, a company specialized in vitro diagnostics and theranostics entered into partnership agreement with Biogaran to supply its Lisa Tracker kits for Biogaran biosimilar monitoring.

In 2018, Novartis AG, entered into an agreement with Endocyte, a US-based Biopharmaceutical Company which develops targeted therapeutics for cancer treatment.

In 2018 RadioMedix Inc. and AREVA Med LLC, announced the Phase 1 trial for AlphaMedixTM in patients with somatostatin receptor positive neuroendocrine tumors in the U.S. AlphaMedixTM is composed of a somatostatin (SST) analogue radiolabeled with 212Pb, an isotope used for Targeted Alpha-emitter Therapy (TAT).

In 2016, avant diagnostics and Amarantus Diagnostics have signed a letter of intent to acquire theranostics health, a protein analysis service provider.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2043

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

mailto:[email protected]

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

#Theranostics Market Growth #Theranostics Market

0 notes

decisionforsight · 3 years

Text

Global Brain Tumor Diagnostics and Therapeutics Market

Global Brain Tumor Diagnostics and Therapeutics Market Size, Share, Growth, Industry Trends and Forecast 2020-2030

The global brain tumor diagnosis and therapeutics market is accounted approximate USD 1.4 billion in 2020 and it is expected to reach approximate USD 4.5 billion by 2030 with a CAGR of 12.5% during forecast period. Brain tumor can occur in any age group. Neurologists treat the tumor on the basis of tumor type, tumor location, and tumor size.A brain tumor is a mass, of abnormal cells in the brain of human body. The skull which encloses the brain is very rigid and growth inside such a restricted space causes various problems. Moreover, brain tumors can be cancerous or non-cancerous. Additionally brain tumor can cause brain damage, and it can be life threatening.

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures) @ https://www.decisionforesight.com/request-sample/DFS020184

Market Dynamics and Factors:

Rising prevalence of brain cancer and growing geriatric population are anticipated to nurture market growth for brain tumor diagnosis and therapeutics. In addition, increasing investment in R&D by the public and private sector for innovating new therapeutics are driving the market. Additionally, increase in investment by government and independent organizations such as the WHO, American brain tumor association, and International brain tumor alliances for supporting of availability of treatment and conducting research on novel cure for the disease is driving the market growth. In addition, evolving diagnostic and radiology services such as Sodium magnetic resonance imaging, chemical exchange saturation transfer, and positron emission tomography are driving the market growth. Moreover, the development of innovative therapeutics and rising awareness about diagnosis among the consumers can be opportunity for the market. However, high cost involved in the diagnosis and treatments of brain tumor is anticipated to hinder the growth of market.

Market Segmentation:

Global Brain Tumor Diagnostics and Therapeutics Market – By Type

Primary Brain Tumor

Secondary Brain Tumor

Global Brain Tumor Diagnostics and Therapeutics Market – By Diagnosis Type

Computed Tomography (CT) Scan

Magnetic Resonance Imaging (MRI)

Pet-Ct Scan

Molecular Testing

Electroencephalogram (EEG)

Tissue Testing

Others

Global Brain Tumor Diagnostics and Therapeutics Market – By Therapeutic Type

Surgery

Radiation Therapy

Targeted Therapy

Chemotherapy

Immunotherapy

Global Brain Tumor Diagnostics and Therapeutics Market – By Geography

North America

U.S.

Canada

Mexico

Europe

U.K.

France

Germany

Italy

Rest of Europe

Asia-Pacific

Japan

China

India

Australia

Rest of Asia Pacific

ROW

Latin America

Middle East

Africa

New Business Strategies, Challenges & Policies are mentioned in Table of Content, Request TOC at @ https://www.decisionforesight.com/toc-request/DFS020184

Geographic Analysis:

North America is dominating the market and is anticipated to maintain same trend during the forecast period. According to research report, in 2017 region held approximate 47% of the global market for brain tumor diagnosis and therapeutics. The U.S. held approximate 88% of the regional market in 2017. The rapid increase in the population suffering from brain tumors in the region is anticipated to market growth. Asia Pacific is anticipated to show fastest growth and expected to maintain same trend during forecast period. Increase in the prevalence of brain tumors, introduction of various technologies and therapies in the region are driving the market growth.

Competitive Scenario:

Some of the key players in global brain tumor diagnosis and therapeutics are Pfizer Inc., Merck & Co. Inc., Hitachi Medical Corporation, Toshiba medical system corporation, Shimadzu Corporation, Siemens healthineers, AstraZeneca Plc, Philips healthcare.

Connect to Analyst @ https://www.decisionforesight.com/speak-analyst/DFS020184

How will this Market Intelligence Report Benefit You?

The report offers statistical data in terms of value (US$) as well as Volume (units) till 2030.

Exclusive insight into the key trends affecting the Global Brain Tumor Diagnostics and Therapeutics industry, although key threats, opportunities and disruptive technologies that could shape the Global Brain Tumor Diagnostics and Therapeutics Market supply and demand.

The report tracks the leading market players that will shape and impact the Global Brain Tumor Diagnostics and Therapeutics Market most.

The data analysis present in the Global Brain Tumor Diagnostics and Therapeutics Market report is based on the combination of both primary and secondary resources.

The report helps you to understand the real effects of key market drivers or retainers on Global Brain Tumor Diagnostics and Therapeutics Market business.

The 2021 Annual Global Brain Tumor Diagnostics and Therapeutics Market offers:

100+ charts exploring and analysing the Global Brain Tumor Diagnostics and Therapeutics Market from critical angles including retail forecasts, consumer demand, production and more

15+ profiles of top producing states, with highlights of market conditions and retail trends

Regulatory outlook, best practices, and future considerations for manufacturers and industry players seeking to meet consumer demand

Benchmark wholesale prices, market position, plus prices for raw materials involved in Global Brain Tumor Diagnostics and Therapeutics Market type

Buy This Premium Research Report@ https://www.decisionforesight.com/checkout/DFS020184

About Us:

Decision Foresight is a market research organization known for its reliable and genuine content, market estimation and the best analysis which is designed to deliver state-of-the-art quality syndicate reports to our customers. Apart from syndicate reports, you will find the best market insights, strategies that will help in taking better business decisions on subjects that may require you to develop and grow your business-like health, science, technology and many more. At Decision Foresight, we truly believe in disseminating the right piece of knowledge to a large section of the audience and cover the in-depth insights of market leaders across various verticals and horizontals.

Contact:

Email: [email protected]

For Latest Update Follow Us:

https://www.facebook.com/Decision-Foresight-110793387201935

https://twitter.com/DecisionFs

https://www.linkedin.com/company/decision-foresight/

0 notes